TRIM63

TRIM63 (MuRF-1) is a striated muscle-specific RING zinc-finger E3 ubiquitin ligase that controls myofibrillar protein homeostasis by targeting sarcomeric proteins for degradation (PMID:11283016, PMID:15967462). It docks at the sarcomeric M-line region through a C-terminal helical domain that binds the titin A168-A170 modules adjacent to the titin kinase, with a loop protrusion in titin mediating recognition (PMID:17215480). TRIM63 binds and ubiquitinates a defined set of myofibrillar substrates—including troponin I, troponin T, myosin light chain 2, myosin heavy chain, and cardiac myosin binding protein C—routing them to proteasomal degradation; loss of TRIM63 reduces ubiquitination of MLC-2 and TnI in vivo (PMID:15967462, PMID:22821932). In cardiomyocytes, TNF-α induces TRIM63 via p42/44 MAPK to drive troponin I ubiquitination and degradation, directly impairing contractility (PMID:17145048). Beyond the sarcomere, TRIM63 mediates fasting- and denervation-induced selective autophagy of endocytosed nicotinic acetylcholine receptors at the neuromuscular junction, co-localizing with SQSTM1, SH3GLB1, and MAP1LC3A on endo/lysosomal vesicles (PMID:24220501). Its expression is transcriptionally driven by FoxO3 in cooperation with SMAD3 and by TAp63/p53, and post-transcriptionally repressed by miR-19a/b (PMID:24920680, PMID:24117217, PMID:26919175). Biallelic loss-of-function variants in TRIM63 cause autosomal-recessive hypertrophic cardiomyopathy, with mutant protein mislocalizing to Z disks, failing to auto-ubiquitinate, and failing to degrade substrates including calcineurin and mTOR, thereby activating mTOR-S6K and calcineurin hypertrophic signaling (PMID:22821932, PMID:32451364).

1. 2001 Medium

   Identifying TRIM63 as a striated muscle-specific RING zinc-finger protein interacting with a SUMO/ubiquitin-like protein established its candidacy as a muscle ubiquitin-pathway component before any substrate was known.

   Evidence Yeast two-hybrid, Co-IP, and RING-domain mutagenesis with fluorescence microscopy in C2C12 cells

   PMID:11283016

   Open questions at the time

   • No catalytic E3 activity demonstrated
   • No physiological substrate identified
   • Nuclear localization in myoblasts not reconciled with later sarcomeric role
2. 2005 High

   Mapping TRIM63 binding to a defined panel of myofibrillar proteins and showing reduced substrate ubiquitination in knockout muscle established it as the in vivo E3 ligase for sarcomeric components.

   Evidence Yeast two-hybrid of skeletal muscle library, peptide-scan binding mapping, Western blot on MuRF-1 KO cardiac tissue

   PMID:15967462

   Open questions at the time

   • In vitro reconstitution of ubiquitin transfer to each substrate not shown
   • Functional consequence of metabolic-enzyme interactions undefined
3. 2007 High

   Solving the titin A168-A170 structure and showing a TRIM63 C-terminal helix binds it with high affinity defined the structural basis of M-line localization.

   Evidence X-ray crystallography, circular dichroism, isothermal calorimetry, SPOTS blots, pull-down assays

   PMID:17215480

   Open questions at the time

   • Functional consequence of docking for substrate selection not established
   • No full-length TRIM63 structure
4. 2006 High

   Linking TNF-α to TRIM63 induction via p42/44 MAPK and to troponin I degradation connected inflammatory signaling to contractile dysfunction in heart failure.

   Evidence Rat CHF model, neonatal cardiomyocyte culture with MAPK inhibitors, siRNA knockdown, contractility measurement

   PMID:17145048

   Open questions at the time

   • Direct E3 transfer of ubiquitin to TnI not reconstituted
   • Whether MAPK acts solely transcriptionally unresolved
5. 2013 High

   Demonstrating TRIM63-dependent selective autophagy of acetylcholine receptors extended its role beyond proteasomal sarcomere turnover to NMJ remodeling.

   Evidence Trim63 KO mice with denervation, immunofluorescence colocalization, reciprocal Co-IP, ATG7 KO comparison

   PMID:24220501

   Open questions at the time

   • Whether TRIM63 ubiquitinates CHRN directly to mark it for autophagy unclear
   • Role of E3 activity vs scaffolding in autophagy undefined
6. 2014 Medium

   Identifying FoxO3/SMAD3 cooperation and miR-19a/b repression defined how TRIM63 levels are set transcriptionally and post-transcriptionally during atrophy and hypertrophy.

   Evidence Promoter luciferase reporters, SBE mutagenesis, ChIP, and 3'UTR luciferase assays with miRNA overexpression

   PMID:24117217 PMID:24920680

   Open questions at the time

   • In vivo contribution of each regulatory input not quantified
   • Interplay between transcriptional and miRNA control untested together
7. 2016 Medium

   Showing TAp63/p53 transactivate the TRIM63 promoter linked TRIM63 to muscle atrophy programs in ALS.

   Evidence Transcriptomic meta-analysis, promoter transactivation reporters, p63 immunohistochemistry in ALS muscle

   PMID:26919175

   Open questions at the time

   • Direct p63 promoter occupancy by ChIP not shown
   • Causal contribution of TRIM63 to ALS atrophy not tested by ablation
8. 2012 High

   HCM patient variants causing Z-disk mislocalization, loss of auto-ubiquitination, and failure to degrade calcineurin/mTOR substrates established a loss-of-function mechanism activating hypertrophic signaling.

   Evidence TRIM63 sequencing in HCM probands, ubiquitination assays, immunofluorescence, inducible transgenic mouse

   PMID:22821932

   Open questions at the time

   • Heterozygous vs biallelic causality not resolved at this stage
   • Whether mutant acts dominant-negative or simple loss undefined
9. 2020 Medium

   A large cohort with familial segregation established that only biallelic TRIM63 variants cause HCM, refining the inheritance model to autosomal recessive.

   Evidence NGS of large HCM cohort, familial segregation, cardiac MRI/echocardiography phenotyping

   PMID:32451364

   Open questions at the time

   • No in vitro protein-function assays in this study
   • Genotype-phenotype correlations across variants incomplete

• How TRIM63 selects between proteasomal degradation and autophagic routing of substrates, and how its M-line docking dictates substrate access, remains unresolved.
• No mechanism linking titin docking to substrate choice
• Determinants of proteasome vs autophagy fate undefined
• Full-length enzyme-substrate structural model lacking